David Geoffrey Bowen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
David Geoffrey Bowen has a total of 230 co-authors. Here are the top co-authors by number of shared publications:
- Geoffrey William McCaughan
Centenary Institute, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia
10 shared publications - Patrick Bertolino
Liver Immunology Group and AW Morrow Gastroenterology and Liver Centre, The University of Sydney and Royal Prince Alfred Hospital, Sydney, NSW, Australia
8 shared publications - Simone Irene Strasser
Royal Prince Alfred Hospital Sydney New South Wales Australia
8 shared publications - Lauren Elise Holz
Department of Microbiology and Immunology, University of Melbourne, The Peter Doherty Institute, Parkville, VIC, Australia
5 shared publications - Nicholas Shackel
Cardiff University
5 shared publications Claire McGuffog
Centenary Institute and The University of Sydney, AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Sydney, Australia
4 shared publications
Latest Publications
- Open Access
- 20 September 2026
- Published by Wiley in Anz Journal of Surgery
Impact of Single Viable Hepatocellular Carcinoma ≤ 3 cm on Survival After Liver Transplantation
Background: The risks of recurrent hepatocellular carcinoma (HCC) and HCC‐specific mortality post‐liver transplant (LT) are influenced by the number and size of viable tumours. This study assesses HCC‐specific mortality post‐transplant for patients in two groups—those with no viable disease versus single viable tumour ≤ 3 cm, as assessed on most recent imaging prior to transplantation. Methods: This retrospective cohort study included adult patients transplanted for the indication of HCC between 1998 and 2018 at two Australian centres. Competing risks regression assessed 5‐year HCC‐specific mortality, with the competing risk of non‐HCC‐specific mortality. Results: There was a significantly lower 5‐year HCC‐specific mortality post‐transplant for those with no viable disease ( n = 152) versus single viable tumour ≤ 3 cm ( n = 145) (4.0% vs. 10.5%, SHR 2.72, 95% CI: 1.06–6.98, p = 0.038) on univariable analysis. On multivariable competing risks analysis, the modified Response Evaluation Criteria In Solid Tumour (mRECIST) criteria and higher AFP level at transplant were significant predictors of 5‐year HCC specific mortality, with progressive disease (aSHR 16.33, 95% CI: 2.35–113.6, p = 0.005) and stable disease (aSHR 10.26, 95% CI: 1.81–58.2, p = 0.0012) having a higher risk than complete response; whilst the significance of no viable disease versus single viable tumour ≤ 3 cm was not significant on multivariable analysis. Conclusions: There was a significantly lower 5‐year HCC‐specific mortality for those with imaging showing no viable disease versus single viable tumour ≤ 3 cm, prior to transplantation. Lower HCC‐specific mortality was demonstrated for those with a lower AFP level and those in radiological complete response at time of transplant.
- 20 September 2026
- Published by Wiley in Anz Journal of Surgery
Open AccessImpact of Single Viable Hepatocellular Carcinoma ≤ 3 cm on Survival After Liver Transplantation
Background: The risks of recurrent hepatocellular carcinoma (HCC) and HCC‐specific mortality post‐liver transplant (LT) are influenced by the number and size of viable tumours. This study assesses HCC‐specific mortality post‐transplant for patients in two groups—those with no viable disease versus single viable tumour ≤ 3 cm, as assessed on most recent imaging prior to transplantation. Methods: This retrospective cohort study included adult patients transplanted for the indication of HCC between 1998 and 2018 at two Australian centres. Competing risks regression assessed 5‐year HCC‐specific mortality, with the competing risk of non‐HCC‐specific mortality. Results: There was a significantly lower 5‐year HCC‐specific mortality post‐transplant for those with no viable disease ( n = 152) versus single viable tumour ≤ 3 cm ( n = 145) (4.0% vs. 10.5%, SHR 2.72, 95% CI: 1.06–6.98, p = 0.038) on univariable analysis. On multivariable competing risks analysis, the modified Response Evaluation Criteria In Solid Tumour (mRECIST) criteria and higher AFP level at transplant were significant predictors of 5‐year HCC specific mortality, with progressive disease (aSHR 16.33, 95% CI: 2.35–113.6, p = 0.005) and stable disease (aSHR 10.26, 95% CI: 1.81–58.2, p = 0.0012) having a higher risk than complete response; whilst the significance of no viable disease versus single viable tumour ≤ 3 cm was not significant on multivariable analysis. Conclusions: There was a significantly lower 5‐year HCC‐specific mortality for those with imaging showing no viable disease versus single viable tumour ≤ 3 cm, prior to transplantation. Lower HCC‐specific mortality was demonstrated for those with a lower AFP level and those in radiological complete response at time of transplant.
- Open Access
Interactions Between Sarcopenia, Physical Frailty and Resting Energy Expenditure in Cirrhosis and Portal Hypertension
Background/Objectives: Sarcopenia and frailty are prevalent and independently prognostic in cirrhosis. Few studies have evaluated both together to ascertain their interaction and phenotypic differences. None have studied their relationship with resting energy expenditure (REE). We simultaneously examined sarcopenia, frailty and REE in a cohort of patients with cirrhosis and portal hypertension—a novel approach. Methods: We retrospectively studied consecutive patients with cirrhosis and portal hypertension, prospectively recruited between 2015 and 2018 to undergo sarcopenia (transversal psoas muscle thickness [TPMT]/height), frailty (Fried Frailty Index [FFI]), and REE assessments via indirect calorimetry. The primary outcome was transplant-free survival (TFS). Results: Ninety-seven patients were recruited with sarcopenia and frailty present in 26% and 40%, respectively. Patients with sarcopenia or frailty alone were phenotypically similar except those with sarcopenia had lower median body mass index (BMI) (23 vs. 28 kg/m2, p = 0.032) and were more likely to be hypermetabolic (60% vs. 0%, p = 0.017). Median TFS was lower in patients with sarcopenia (3.6 months) or frailty (4.5 months), compared to those with neither (10.3 months), while patients with both sarcopenia and frailty exhibited the worst TFS (1.8 months, log-rank p = 0.001). Independent predictors of death or liver transplant were sarcopenia, hepatic encephalopathy, and a higher model for end-stage liver disease score. Conclusions: In patients with cirrhosis and portal hypertension, sarcopenia and physical frailty are related but have differences in BMI and REE. The deleterious impact of sarcopenia and frailty on TFS are additive. Sarcopenia remains an independent predictor of TFS after adjusting for frailty.
Open AccessInteractions Between Sarcopenia, Physical Frailty and Resting Energy Expenditure in Cirrhosis and Portal Hypertension
Background/Objectives: Sarcopenia and frailty are prevalent and independently prognostic in cirrhosis. Few studies have evaluated both together to ascertain their interaction and phenotypic differences. None have studied their relationship with resting energy expenditure (REE). We simultaneously examined sarcopenia, frailty and REE in a cohort of patients with cirrhosis and portal hypertension—a novel approach. Methods: We retrospectively studied consecutive patients with cirrhosis and portal hypertension, prospectively recruited between 2015 and 2018 to undergo sarcopenia (transversal psoas muscle thickness [TPMT]/height), frailty (Fried Frailty Index [FFI]), and REE assessments via indirect calorimetry. The primary outcome was transplant-free survival (TFS). Results: Ninety-seven patients were recruited with sarcopenia and frailty present in 26% and 40%, respectively. Patients with sarcopenia or frailty alone were phenotypically similar except those with sarcopenia had lower median body mass index (BMI) (23 vs. 28 kg/m2, p = 0.032) and were more likely to be hypermetabolic (60% vs. 0%, p = 0.017). Median TFS was lower in patients with sarcopenia (3.6 months) or frailty (4.5 months), compared to those with neither (10.3 months), while patients with both sarcopenia and frailty exhibited the worst TFS (1.8 months, log-rank p = 0.001). Independent predictors of death or liver transplant were sarcopenia, hepatic encephalopathy, and a higher model for end-stage liver disease score. Conclusions: In patients with cirrhosis and portal hypertension, sarcopenia and physical frailty are related but have differences in BMI and REE. The deleterious impact of sarcopenia and frailty on TFS are additive. Sarcopenia remains an independent predictor of TFS after adjusting for frailty.
- Open Access
- 10 February 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-17
A hepatic network of dendritic cells mediates CD4 T cell help outside lymphoid organs
While CD4+ T cells are a prerequisite for CD8+ T cell-mediated protection against intracellular hepatotropic pathogens, the mechanisms facilitating the transfer of CD4-help to intrahepatic CD8+ T cells are unknown. Here, we developed an experimental system to investigate cognate CD4+ and CD8+ T cell responses to a model-antigen expressed de novo in hepatocytes and reveal that after initial priming, effector CD4+ and CD8+ T cells migrate into portal tracts and peri-central vein regions of the liver where they cluster with type-1 conventional dendritic cells. These dendritic cells are locally licensed by CD4+ T cells and expand the number of CD8+ T cells in situ, resulting in larger effector and memory CD8+ T cell pools. These findings reveal that CD4+ T cells promote intrahepatic immunity by amplifying the CD8+ T cell response via peripheral licensing of hepatic type-1 conventional dendritic cells and identify intrahepatic perivascular compartments specialized in facilitating effector T cell-dendritic cell interactions.
- 10 February 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-17
Open AccessA hepatic network of dendritic cells mediates CD4 T cell help outside lymphoid organs
While CD4+ T cells are a prerequisite for CD8+ T cell-mediated protection against intracellular hepatotropic pathogens, the mechanisms facilitating the transfer of CD4-help to intrahepatic CD8+ T cells are unknown. Here, we developed an experimental system to investigate cognate CD4+ and CD8+ T cell responses to a model-antigen expressed de novo in hepatocytes and reveal that after initial priming, effector CD4+ and CD8+ T cells migrate into portal tracts and peri-central vein regions of the liver where they cluster with type-1 conventional dendritic cells. These dendritic cells are locally licensed by CD4+ T cells and expand the number of CD8+ T cells in situ, resulting in larger effector and memory CD8+ T cell pools. These findings reveal that CD4+ T cells promote intrahepatic immunity by amplifying the CD8+ T cell response via peripheral licensing of hepatic type-1 conventional dendritic cells and identify intrahepatic perivascular compartments specialized in facilitating effector T cell-dendritic cell interactions.
- Open Access
- 25 April 2023
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 38 (8) , 1325-1332
Epidemiology, characteristics, and outcomes of patients with acute‐on‐chronic liver failure in Australia
Background and Aim: Acute‐on‐chronic liver failure (ACLF) is distinct from acute decompensation (AD) of cirrhosis in its clinical presentation, pathophysiology, and prognosis. There are limited published Australian ACLF data.Methods: We performed a single‐center retrospective cohort study of all adults with cirrhosis admitted with a decompensating event to a liver transplantation (LT) centre between 2015 and 2020. ACLF was defined using the European Association for the Study of the Liver‐Chronic Liver Failure (EASL‐CLIF) definition while those who did not meet the definition were classified as AD. The primary outcome of interest was 90‐day LT‐free survival.Results: A total of 615 patients had 1039 admissions for a decompensating event. On their index admission, 34% (209/615) of patients were classified as ACLF. Median admission model for end‐stage liver disease (MELD) and MELD‐Na scores were higher in ACLF patients compared with AD (21 vs 17 and 25 vs 20 respectively, both P < 0.001). Both the presence and severity of ACLF (grade ≥ 2) significantly predicted worse LT‐free survival compared with patients with AD. The EASL‐CLIF ACLF score (CLIF‐C ACLF), MELD and MELD‐Na scores performed similarly in predicting 90‐day mortality. Patients with index ACLF had a higher risk of 28‐day mortality (28.1% vs 5.1%, P < 0.001) and shorter times to readmission compared with those with AD.Conclusion: ACLF complicates over a third of hospital admissions for cirrhosis with decompensating events and is associated with a high short‐term mortality. The presence and grade of ACLF predicts 90‐day mortality and should be identified as those at greatest risk of poor outcome without intervention such as LT.
- 25 April 2023
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 38 (8) , 1325-1332
Open AccessEpidemiology, characteristics, and outcomes of patients with acute‐on‐chronic liver failure in Australia
Background and Aim: Acute‐on‐chronic liver failure (ACLF) is distinct from acute decompensation (AD) of cirrhosis in its clinical presentation, pathophysiology, and prognosis. There are limited published Australian ACLF data.Methods: We performed a single‐center retrospective cohort study of all adults with cirrhosis admitted with a decompensating event to a liver transplantation (LT) centre between 2015 and 2020. ACLF was defined using the European Association for the Study of the Liver‐Chronic Liver Failure (EASL‐CLIF) definition while those who did not meet the definition were classified as AD. The primary outcome of interest was 90‐day LT‐free survival.Results: A total of 615 patients had 1039 admissions for a decompensating event. On their index admission, 34% (209/615) of patients were classified as ACLF. Median admission model for end‐stage liver disease (MELD) and MELD‐Na scores were higher in ACLF patients compared with AD (21 vs 17 and 25 vs 20 respectively, both P < 0.001). Both the presence and severity of ACLF (grade ≥ 2) significantly predicted worse LT‐free survival compared with patients with AD. The EASL‐CLIF ACLF score (CLIF‐C ACLF), MELD and MELD‐Na scores performed similarly in predicting 90‐day mortality. Patients with index ACLF had a higher risk of 28‐day mortality (28.1% vs 5.1%, P < 0.001) and shorter times to readmission compared with those with AD.Conclusion: ACLF complicates over a third of hospital admissions for cirrhosis with decompensating events and is associated with a high short‐term mortality. The presence and grade of ACLF predicts 90‐day mortality and should be identified as those at greatest risk of poor outcome without intervention such as LT.
- Open Access
- 21 February 2023
- Published by Wolters Kluwer Health in Transplantation
- Vol. 107 (3) , 556-557
Transforming Genes to Protect Against Liver Disease: Will siRNA-based Therapeutics Reduce the Need for Liver Transplantation?
- 21 February 2023
- Published by Wolters Kluwer Health in Transplantation
- Vol. 107 (3) , 556-557
Open AccessTransforming Genes to Protect Against Liver Disease: Will siRNA-based Therapeutics Reduce the Need for Liver Transplantation?
- Open Access
- 19 June 2022
- Published by Wiley in Immunology & Cell Biology
- Vol. 100 (6) , 394-408
The liver contains distinct interconnected networks of CX3CR1+ macrophages, XCR1+ type 1 and CD301a+ type 2 conventional dendritic cells embedded within portal tracts
Portal tracts are key intrahepatic structures where leukocytes accumulate during immune responses. They contain the blood inflow, which includes portal blood from the gut, and lymphatic and biliary outflow of the liver, and as such represent a key interface for potential pathogen entry to the liver. Myeloid cells residing in the interstitium of the portal tract might play an important role in the surveillance or prevention of pathogen dissemination; however, the exact composition and localization of this population has not been explored fully. Our in‐depth characterization of portal tract myeloid cells revealed that in addition to T lymphocytes, portal tracts contain a heterogeneous population of MHCIIhigh myeloid cells with potential antigen presenting cell (APC) function. These include a previously unreported subset of CSF1R‐dependent CX3CR1+ macrophages that phenotypically and morphologically resemble liver capsular macrophages, as well as the two main dendritic cell subsets (cDC1 and cDC2). These cells are not randomly distributed, but each subset forms interconnected networks intertwined with specific components of the portal tract. The CX3CR1+ cells were preferentially detected along the outer border of the portal tracts, and also in the portal interstitium adjacent to the portal vein, bile duct, lymphatic vessels and hepatic artery. cDC1s abounded along the lymphatic vessels, while cDC2s mostly surrounded the biliary tree. The specific distributions of these discrete subsets predict that they may serve distinct functions in this compartment. Overall, our findings suggest that portal tracts and their embedded cellular networks of myeloid cells form a distinctive lymphoid compartment in the liver that has the potential to orchestrate immune responses in this organ.
- 19 June 2022
- Published by Wiley in Immunology & Cell Biology
- Vol. 100 (6) , 394-408
Open AccessThe liver contains distinct interconnected networks of CX3CR1+ macrophages, XCR1+ type 1 and CD301a+ type 2 conventional dendritic cells embedded within portal tracts
Portal tracts are key intrahepatic structures where leukocytes accumulate during immune responses. They contain the blood inflow, which includes portal blood from the gut, and lymphatic and biliary outflow of the liver, and as such represent a key interface for potential pathogen entry to the liver. Myeloid cells residing in the interstitium of the portal tract might play an important role in the surveillance or prevention of pathogen dissemination; however, the exact composition and localization of this population has not been explored fully. Our in‐depth characterization of portal tract myeloid cells revealed that in addition to T lymphocytes, portal tracts contain a heterogeneous population of MHCIIhigh myeloid cells with potential antigen presenting cell (APC) function. These include a previously unreported subset of CSF1R‐dependent CX3CR1+ macrophages that phenotypically and morphologically resemble liver capsular macrophages, as well as the two main dendritic cell subsets (cDC1 and cDC2). These cells are not randomly distributed, but each subset forms interconnected networks intertwined with specific components of the portal tract. The CX3CR1+ cells were preferentially detected along the outer border of the portal tracts, and also in the portal interstitium adjacent to the portal vein, bile duct, lymphatic vessels and hepatic artery. cDC1s abounded along the lymphatic vessels, while cDC2s mostly surrounded the biliary tree. The specific distributions of these discrete subsets predict that they may serve distinct functions in this compartment. Overall, our findings suggest that portal tracts and their embedded cellular networks of myeloid cells form a distinctive lymphoid compartment in the liver that has the potential to orchestrate immune responses in this organ.
- Open Access
- 13 May 2022
- Published by Springer Nature in BMC Medical Education
- Vol. 22 (1) , 1-12
Research supervisors’ views of barriers and enablers for research projects undertaken by medical students; a mixed methods evaluation of a post-graduate medical degree research project program
Background: Medical degree programs use scholarly activities to support development of basic research skills, critical evaluation of medical information and promotion of medical research. The University of Sydney Doctor of Medicine Program includes a compulsory research project. Medical student projects are supervised by academic staff and affiliates, including biomedical science researchers and clinician-academics. This study investigated research supervisors’ observations of the barriers to and enablers of successful medical student research projects. Methods: Research supervisors (n = 130) completed an anonymous, online survey after the completion of the research project. Survey questions targeted the research supervisors’ perceptions of barriers to successful completion of projects and sources of support for their supervision of the student project. Data were analysed by descriptive statistics and using manifest content analysis. Further quantitative investigation was made by cross-tabulation according to prior research supervision experience. Results: Research supervisors reported that students needed both generic skills (75%) and research-based skills (71%) to successfully complete the project. The major barrier to successful research projects was the lack of protected time for research activities (61%). The assessment schedule with compulsory progress milestones enabled project completion (75%), and improved scientific presentation (90%) and writing (93%) skills. Supervisors requested further support for their students for statistics (75%), scientific writing (51%), and funding for projects (52%). Prior research supervision experience influenced the responses. Compared to novice supervisors, highly experienced supervisors were significantly more likely to want students to be allocated dedicated time for the project (P < 0.01) and reported higher rates of access to expert assistance in scientific writing, preparing ethics applications and research methodology. Novice supervisors reported higher rates of unexpected project delays and data acquisition problems (P < 0.05). Co-supervision was favoured by experienced supervisors but rejected by novice supervisors. Conclusions: Both generic and research-related skills were important for medical student research project success. Overall, protected research time, financial and other academic support were identified as factors that would improve the research project program. Prior research supervision experience influences perceptions of program barriers and enablers. These findings will inform future support needs for projects and research supervisor training for the research supervision role.
- 13 May 2022
- Published by Springer Nature in BMC Medical Education
- Vol. 22 (1) , 1-12
Open AccessResearch supervisors’ views of barriers and enablers for research projects undertaken by medical students; a mixed methods evaluation of a post-graduate medical degree research project program
Background: Medical degree programs use scholarly activities to support development of basic research skills, critical evaluation of medical information and promotion of medical research. The University of Sydney Doctor of Medicine Program includes a compulsory research project. Medical student projects are supervised by academic staff and affiliates, including biomedical science researchers and clinician-academics. This study investigated research supervisors’ observations of the barriers to and enablers of successful medical student research projects. Methods: Research supervisors (n = 130) completed an anonymous, online survey after the completion of the research project. Survey questions targeted the research supervisors’ perceptions of barriers to successful completion of projects and sources of support for their supervision of the student project. Data were analysed by descriptive statistics and using manifest content analysis. Further quantitative investigation was made by cross-tabulation according to prior research supervision experience. Results: Research supervisors reported that students needed both generic skills (75%) and research-based skills (71%) to successfully complete the project. The major barrier to successful research projects was the lack of protected time for research activities (61%). The assessment schedule with compulsory progress milestones enabled project completion (75%), and improved scientific presentation (90%) and writing (93%) skills. Supervisors requested further support for their students for statistics (75%), scientific writing (51%), and funding for projects (52%). Prior research supervision experience influenced the responses. Compared to novice supervisors, highly experienced supervisors were significantly more likely to want students to be allocated dedicated time for the project (P < 0.01) and reported higher rates of access to expert assistance in scientific writing, preparing ethics applications and research methodology. Novice supervisors reported higher rates of unexpected project delays and data acquisition problems (P < 0.05). Co-supervision was favoured by experienced supervisors but rejected by novice supervisors. Conclusions: Both generic and research-related skills were important for medical student research project success. Overall, protected research time, financial and other academic support were identified as factors that would improve the research project program. Prior research supervision experience influences perceptions of program barriers and enablers. These findings will inform future support needs for projects and research supervisor training for the research supervision role.
- Open Access
The Relationship of Obesity, Nutritional Status and Muscle Wasting in Patients Assessed for Liver Transplantation
Introduction: Obesity co-exists with malnutrition and muscle atrophy in patients with cirrhosis. Muscle wasting is a feature of sarcopenia, a known determinant of patient outcomes. This is the first description of a relationship between obesity, subjective global assessment (SGA) of nutritional status and muscle wasting in patients with cirrhosis. Methods: The relationship between body mass index (BMI with obesity defined as ≥ 30 kg/m2), nutritional status (assessed by liver-specific subjective global assessment—SGA) and muscle wasting (assessed by corrected total cross-sectional psoas muscle area—cTPA) was analysed in patients with cirrhosis considered for liver transplantation between 1 January 2012 and 31 December 2014. Results: There were 205 patients, of whom 70% were males. The mean age was 52 ± 0.7 years and the Model for End-Stage Liver Disease (MELD) score was 16.8 ± 0.5. Overall, 31% of patients were obese and 56% of well-nourished (SGA A) individuals were obese. Muscle wasting was identified in 86% of all patients, irrespective of their nutritional status (A, B, C). All obese males classified as well-nourished (SGA A) were sarcopenic and 62% of obese females classified as SGA A were sarcopenic. Muscle wasting was worse in obese individuals (cTPA 230.9 mm2/m2 ± 12.9, p < 0.0001) and more likely to be associated with hepatic encephalopathy (p = 0.03). Univariate and multivariate analysis demonstrated testosterone deficiency was significantly associated with muscle wasting (p = 0.007) but not obesity (p = 0.8). Conclusion: Obesity combined with muscle wasting is common in patients with cirrhosis. Muscle wasting is common in well-nourished (SGA A) obese patients. Consequently, all patients assessed for liver transplantation should undergo additional screening for malnutrition and muscle wasting irrespective of BMI.
Open AccessThe Relationship of Obesity, Nutritional Status and Muscle Wasting in Patients Assessed for Liver Transplantation
Introduction: Obesity co-exists with malnutrition and muscle atrophy in patients with cirrhosis. Muscle wasting is a feature of sarcopenia, a known determinant of patient outcomes. This is the first description of a relationship between obesity, subjective global assessment (SGA) of nutritional status and muscle wasting in patients with cirrhosis. Methods: The relationship between body mass index (BMI with obesity defined as ≥ 30 kg/m2), nutritional status (assessed by liver-specific subjective global assessment—SGA) and muscle wasting (assessed by corrected total cross-sectional psoas muscle area—cTPA) was analysed in patients with cirrhosis considered for liver transplantation between 1 January 2012 and 31 December 2014. Results: There were 205 patients, of whom 70% were males. The mean age was 52 ± 0.7 years and the Model for End-Stage Liver Disease (MELD) score was 16.8 ± 0.5. Overall, 31% of patients were obese and 56% of well-nourished (SGA A) individuals were obese. Muscle wasting was identified in 86% of all patients, irrespective of their nutritional status (A, B, C). All obese males classified as well-nourished (SGA A) were sarcopenic and 62% of obese females classified as SGA A were sarcopenic. Muscle wasting was worse in obese individuals (cTPA 230.9 mm2/m2 ± 12.9, p < 0.0001) and more likely to be associated with hepatic encephalopathy (p = 0.03). Univariate and multivariate analysis demonstrated testosterone deficiency was significantly associated with muscle wasting (p = 0.007) but not obesity (p = 0.8). Conclusion: Obesity combined with muscle wasting is common in patients with cirrhosis. Muscle wasting is common in well-nourished (SGA A) obese patients. Consequently, all patients assessed for liver transplantation should undergo additional screening for malnutrition and muscle wasting irrespective of BMI.
- Open Access
Supplementation with Synbiotics and/or Branched Chain Amino Acids in Hepatic Encephalopathy: A Pilot Randomised Placebo-Controlled Clinical Study
Introduction: Hepatic encephalopathy (HE) is common in patients with cirrhosis and is characterised by reduced hepatic ammonia clearance. This is accompanied by alterations in gut bacteria that may be ameliorated with synbiotics (pro- and prebiotics). Branched chain amino acids (BCAAs) are thought to have a role in the detoxification of ammonia. We investigated the effects of the administration of synbiotics and/or BCAAs in treating HE. Methods: Participants with overt HE were randomised in a blinded placebo-controlled study to receive synbiotics, BCAAs, or a combination of BCAAs and Synbiotics. Relevant biochemical and nutritional data and depression and anxiety scores (DASS-21) were collected at entry, 4 weeks, and on completion, at 8 weeks. The Trail Making Test (TMT) and Inhibitory Control Test (ICT) were used to assess cognitive function in patients withHE. Results were analysed using linear mixed effects regression analyses. Results: Sixty-one participants were enrolled and 49 who returned for at least 1 follow-up review were included in the intention to treat analysis. The mean age was 55.8 ± 6.1 years and 86% were males. Despite evidence of a placebo effect, there was significant improvement in TMT B and ICT weighted lures in participants who received combined synbiotics/BCAAs treatment compared to placebo at study completion (p ≤ 0.05). Cognitive improvement occurred without a significant change in ammonia levels. Conclusion: To our knowledge, this is the first study reporting that combined synbiotics and BCAAs improve HE, and that may be beneficial in the management of HE. A larger study is needed to confirm these results.
Open AccessSupplementation with Synbiotics and/or Branched Chain Amino Acids in Hepatic Encephalopathy: A Pilot Randomised Placebo-Controlled Clinical Study
Introduction: Hepatic encephalopathy (HE) is common in patients with cirrhosis and is characterised by reduced hepatic ammonia clearance. This is accompanied by alterations in gut bacteria that may be ameliorated with synbiotics (pro- and prebiotics). Branched chain amino acids (BCAAs) are thought to have a role in the detoxification of ammonia. We investigated the effects of the administration of synbiotics and/or BCAAs in treating HE. Methods: Participants with overt HE were randomised in a blinded placebo-controlled study to receive synbiotics, BCAAs, or a combination of BCAAs and Synbiotics. Relevant biochemical and nutritional data and depression and anxiety scores (DASS-21) were collected at entry, 4 weeks, and on completion, at 8 weeks. The Trail Making Test (TMT) and Inhibitory Control Test (ICT) were used to assess cognitive function in patients withHE. Results were analysed using linear mixed effects regression analyses. Results: Sixty-one participants were enrolled and 49 who returned for at least 1 follow-up review were included in the intention to treat analysis. The mean age was 55.8 ± 6.1 years and 86% were males. Despite evidence of a placebo effect, there was significant improvement in TMT B and ICT weighted lures in participants who received combined synbiotics/BCAAs treatment compared to placebo at study completion (p ≤ 0.05). Cognitive improvement occurred without a significant change in ammonia levels. Conclusion: To our knowledge, this is the first study reporting that combined synbiotics and BCAAs improve HE, and that may be beneficial in the management of HE. A larger study is needed to confirm these results.